Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study

被引:38
作者
Almagro, Pere [1 ]
Martinez-Camblor, Pablo [2 ]
Soriano, Joan B. [3 ]
Marin, Jose M. [4 ]
Alfageme, Inmaculada [5 ,6 ]
Casanova, Ciro
Esteban, Cristobal [7 ]
Soler-Cataluna, Juan J. [8 ]
De-Torres, Juan P. [9 ]
Celli, Bartolome R. [10 ]
Miravitlles, Marc [11 ]
机构
[1] Hosp Univ Mutua Terrassa, Dept Internal Med, Acute Geriatr Care Unit, Barcelona, Spain
[2] Asturias Biomed Res Off, Oviedo, Spain
[3] Hosp Univ Son Espases, Fdn Invest Saniat Illes Balers, Balearic Islands, Spain
[4] Hosp Univ Miguel Servet, Resp Dept, Zaragoza, Spain
[5] Valme Univ Hosp, Resp Dept, Seville, Spain
[6] Hosp Nuestra Senora Candelaria, Resp Dept, Tenerife, Spain
[7] Hosp Galdakao Usansolo, Resp Dept, Bizkaia, Spain
[8] Hosp Arnau Vilanova, Resp Dept, Valencia, Spain
[9] Cli nica Univ Navarra, Resp Dept, Pamplona, Spain
[10] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA
[11] Hosp Univ Vall dHebron, Dept Pneumol, CIBER Enfermedades Resp CIBERES, Barcelona, Spain
来源
PLOS ONE | 2014年 / 9卷 / 02期
关键词
OBSTRUCTIVE PULMONARY-DISEASE; BODE INDEX; MORTALITY; RISK; CLASSIFICATION; EXACERBATIONS; COMORBIDITY; DISABILITY; SEVERITY; OUTCOMES;
D O I
10.1371/journal.pone.0089866
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: FEV1 is universally used as a measure of severity in COPD. Current thresholds are based on expert opinion and not on evidence. Objectives: We aimed to identify the best FEV1 (% predicted) and dyspnea (mMRC) thresholds to predict 5-yr survival in COPD patients. Design and Methods: We conducted a patient-based pooled analysis of eleven COPD Spanish cohorts (COCOMICS). Survival analysis, ROC curves, and C-statistics were used to identify and compare the best FEV1 (%) and mMRC scale thresholds that predict 5-yr survival. Results: A total of 3,633 patients (93% men), totaling 15,878 person-yrs. were included, with a mean age 66.469.7, and predicted FEV1 of 53.8% (+/- 19.4%). Overall 975 (28.1%) patients died at 5 years. The best thresholds that spirometrically split the COPD population were: mild >= 70%, moderate 56-69%, severe 36-55%, and very severe <= 35%. Survival at 5 years was 0.89 for patients with FEV1 >= 70 vs. 0.46 in patients with FEV1 <= 35% (H. R: 6; 95% C. I.: 4.69-7.74). The new classification predicts mortality significantly better than dyspnea (mMRC) or FEV1 GOLD and BODE cutoffs (all p<0.001). Prognostic reliability is maintained at 1, 3, 5, and 10 years. In younger patients, survival was similar for FEV1 (%) values between 70% and 100%, whereas in the elderly the relationship between FEV1 (%) and mortality was inversely linear. Conclusions: The best thresholds for 5-yr survival were obtained stratifying FEV1 (%) by >= 70%, 56-69%, 36-55%, and <= 35%. These cutoffs significantly better predict mortality than mMRC or FEV1 (%) GOLD and BODE cutoffs.
引用
收藏
页数:7
相关论文
共 42 条
  • [31] The Usefulness of the Pretreatment Neutrophil/Lymphocyte Ratio as a Predictor of the 5-Year Survival in Stage 1-3 Triple Negative Breast Cancer Patients
    Azab, Basem
    Amundson, Julia R.
    Cioci, Alessia
    Stuart, Heather
    Yakoub, Danny
    Avisar, Eli
    Moffat, Fredrick
    Livingstone, Alan S.
    Franceschi, Dido
    BREAST CARE, 2021, 16 (01) : 43 - 49
  • [32] Effects of Emergency Medical Service Response Time on Survival Rate of Out-of-Hospital Cardiac Arrest Patients: a 5-Year Retrospective Study
    Damdin, Siriporn
    Trakulsrichai, Satariya
    Yuksen, Chaiyaporn
    Sricharoen, Pungkava
    Suttapanit, Karn
    Tienpratarn, Welawat
    Liengswangwong, Wijittra
    Seesuklom, Suteenun
    ARCHIVES OF ACADEMIC EMERGENCY MEDICINE, 2025, 13 (01)
  • [33] Novel Urinary Glycan Biomarkers Predict Cardiovascular Events in Patients With Type 2 Diabetes: A Multicenter Prospective Study With 5-Year Follow Up (U-CARE Study 2)
    Mise, Koki
    Imamura, Mariko
    Yamaguchi, Satoshi
    Watanabe, Mayu
    Higuchi, Chigusa
    Katayama, Akihiro
    Miyamoto, Satoshi
    Uchida, Haruhito A.
    Nakatsuka, Atsuko
    Eguchi, Jun
    Hida, Kazuyuki
    Nakato, Tatsuaki
    Tone, Atsuhito
    Teshigawara, Sanae
    Matsuoka, Takashi
    Kamei, Shinji
    Murakami, Kazutoshi
    Shimizu, Ikki
    Miyashita, Katsuhiro
    Ando, Shinichiro
    Nunoue, Tomokazu
    Yoshida, Michihiro
    Yamada, Masao
    Shikata, Kenichi
    Wada, Jun
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [34] Platelet Count, ADAMTS13 Activity, von Willebrand Factor Level and Survival in Patients with Colorectal Cancer: 5-Year Follow-up Study
    Garam, Nora
    Malati, Eva
    Sinkovits, Gyorgy
    Gombos, Timea
    Szederjesi, Attila
    Barabas, Lorand
    Graf, Laszlo
    Kocsis, Judit
    Prohaszka, Zoltan
    THROMBOSIS AND HAEMOSTASIS, 2018, 118 (01) : 123 - 131
  • [35] 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study
    Luo, Yung-Hung
    Luo, Lei
    Wampfler, Jason A.
    Wang, Yi
    Liu, Dan
    Chen, Yuh-Min
    Adjei, Alex A.
    Midthun, David E.
    Yang, Ping
    LANCET ONCOLOGY, 2019, 20 (08) : 1098 - 1108
  • [36] Nomogram for predicting 1-, 5-, and 10-year survival in hemodialysis (HD) patients: a single center retrospective study
    Ouyang, Han
    Shi, Qiuhong
    Zhu, Jing
    Shen, Huaying
    Jiang, Shan
    Song, Kai
    RENAL FAILURE, 2021, 43 (01) : 1508 - 1519
  • [37] Perioperative Blood Glucose Levels &lt;150 mg/dL are Associated With Improved 5-Year Survival in Patients Undergoing On-Pump Cardiac Surgery A Prospective, Observational Cohort Study
    Mansur, Ashham
    Popov, Aron Frederik
    Ameen, Abu Hanna
    Bergmann, Ingo
    Brandes, Ivo Florian
    Beissbarth, Tim
    Bauer, Martin
    Hinz, Jose
    MEDICINE, 2015, 94 (45) : e2035
  • [38] Sustained IL-6 and sTNF-αR1 levels after hip fracture predict 5-year mortality: A prospective cohort study from the Baltimore Hip Studies
    Camara, Saionara M. A.
    Hochberg, Marc C.
    Miller, Ram
    Ryan, Alice S.
    Orwig, Denise
    Gruber-Baldini, Ann L.
    Guralnik, Jack
    Magder, Laurence S.
    Feng, Zhaoyong
    Falvey, Jason R.
    Beamer, Brock A.
    Magaziner, Jay
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 (09) : 2644 - 2655
  • [39] The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease
    Kapur, Akhil
    Bartolini, Davide
    Finlay, Malcolm C.
    Qureshi, Ayesha C.
    Flather, Marcus
    Strange, Julian W.
    Hall, Roger J.
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2010, 11 (01) : 26 - 33
  • [40] Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial
    Hoeijmakers, L. L.
    Rozeman, E. A.
    Lopez-Yurda, M.
    Grijpink-Ongering, L. G.
    Heeres, B. C.
    van de Wiel, B. A.
    Flohil, C.
    Sari, A.
    Heijmink, S. W. T. P. J.
    van den Broek, D.
    Broeks, A.
    de Groot, J. W. B.
    Vollebergh, M. A.
    Wilgenhof, S.
    van Thienen, J. V.
    Haanen, J. B. A. G.
    Blank, C. U.
    EUROPEAN JOURNAL OF CANCER, 2025, 222